Precision Medicine in Oncology® | Specialty

The OncLive Precision Medicine in Oncology® condition center page is a comprehensive resource for clinical news and expert insights on precision-focused approaches in patients with cancer, with gene-targeted tyrosine kinase inhibitors and antibody-drug conjugates, checkpoint inhibitors, tumor-infiltrating lymphocyte therapy, and other tailored treatments. This page features news articles, interviews in written and video format, and podcasts that focus on updates and ongoing research with personalized therapies across solid and hematologic tumors.

Hotspot ESR1 Mutations Drive Tumor Stickiness in Metastatic Endocrine-Resistant Breast Cancer

May 24th 2022

The prevalence of ESR1 mutations in endocrine-resistant metastatic breast cancer has paved an avenue for investigators to explore their role in the promotion of metastasis.

Dr. Lee on the Importance of Collaboration in Precision Medicine

May 23rd 2022

Kelvin P. Lee, MD, discusses the importance of collaboration in precision medicine.

European Approval Sought for Adagrasib in Previously Treated KRAS G12C–Mutated NSCLC

May 20th 2022

A marketing authorization application has been submitted to the European Medicines Agency seeking the approval of adagrasib for therapeutic use in previously treated patients with non–small cell lung cancer harboring a KRAS G12C mutation.

Inside the Clinic: Experts Explore Case Studies in DLBCL

May 16th 2022

Maher Albitar, MD, and Andre H. Goy, MD, discuss case studies in diffuse large B-cell lymphoma.

Inside the Clinic: Experts Discuss Testing for Molecular Abnormalities in AML

May 13th 2022

Maher Albitar, MD, and Andre H. Goy, MD, discuss the importance of testing for molecular abnormalities in acute myeloid leukemia.

Inside the Clinic: Experts Highlight Molecular Complexities in MCL

May 13th 2022

Maher Albitar, MD, and Andre H. Goy, MD, share insights regarding molecular complexities in mantle cell lymphoma.

Superagonists Pull IL-15 Into Focus in Oncology Care

May 11th 2022

Following in the footsteps of the cytokine interleukin-2, IL-15 affords investigators similar qualities as a target without the associated toxicities of its immunotherapeutic predecessor.

PARP Inhibitors Are Under Study as Treatment Options Beyond BRCA-Mutated Breast Cancer

May 9th 2022

Virginia G. Kaklamani, MD, discussed the emerging role of PARP inhibitors, practice-changing updates in HER2-positive breast cancer, the utilization of CDK4/6 inhibitors in hormone receptor–positive, HER2-negative breast cancer, and the various therapeutic classes and their effects on care in triple-negative breast cancer.

FDA Grants Fast Track Status to HM43239 for FLT3-Mutated, Relapsed/Refractory AML

May 4th 2022

The FDA has granted a fast track designation to the myeloid kinome inhibitor, HM43239, for use as a potential therapeutic option in patients with relapsed or refractory acute myeloid leukemia whose tumors harbor a FLT3 mutation.

Biomarker Testing Will Fuel Next Wave of Treatment Innovations in Breast Cancer

May 1st 2022

Christos Vaklavas, MD, discusses the increasing emphasis on investigating tumor biology in breast cancer, plus the evolving treatment landscapes in HER2-positive breast cancer, hormone receptor–positive, HER2-negative breast cancer, and triple-negative breast cancer.

Microbiota Modulation Offers Hope of Expanding the Benefits of Immunotherapy

April 28th 2022

Novel strategies to modulate the microbiota are now an area of robust investigation

Novel Agents Continue to Drive Treatment of NSCLC With EGFR, MET, and ALK Abnormalities

April 27th 2022

Jun Zhang, MD, PhD, discusses key clinical trials utilizing immunotherapy in non–small cell lung cancer, the continued importance of biomarker testing to help inform treatment decisions, and targeted therapies for EGFR, MET, and ALK mutations.

Dr. Lee on the Importance of Sequencing in Precision Medicine

April 27th 2022

Kelvin P. Lee, MD, discusses the importance of sequencing in precision medicine.

Tissue Is Still the Issue: Pathology Expert Discusses Clinical Needs in the Molecular Era

April 26th 2022

Lynette M. Sholl, MD, discusses why cancer pathologists still want better tissue samples.

EU Panel Recommends Capmatinib for METex14-Altered Advanced NSCLC

April 23rd 2022

The European Medicines Agency’s Committee for Medicinal Products for Human Use has recommended granting marketing authorization to capmatinib for use as a single agent in select adult patients with advanced non–small cell lung cancer harboring a METex14 skipping alteration.

State of Science Summit- Precision Medicine - Lung Cancer: Chaired by Karen L. Reckamp, MD, MS

April 21st 2022

State of Science Summit- Precision Medicine - Lung Cancer: Chaired by Karen L. Reckamp, MD, MS

KIN-3248 Under Exploration in Advanced Solid Tumors Harboring FGFR2 and/or FGFR3 Alterations

April 21st 2022

The safety, tolerability, and preliminary efficacy of the irreversible, small molecule pan-FGFR inhibitor KIN-3248 is under investigation in adult patients with advanced tumors harboring FGFR2 and/or FGFR3 gene alterations, as part of the phase 1 KN-4802 trial.

Dr. Fausel on the Evolution of Genomic Testing in Cancer Care

April 21st 2022

Christopher A. Fausel, PharmD, MHA, BCOP, discusses how genetic sequencing has played a growing role in cancer care.

Targeted Treatment Boom Reshapes Differentiated Thyroid Cancer Landscape

April 18th 2022

Marcia S. Brose, MD, PhD, FASCO, and a panel of thyroid cancer experts share their insights into the evolving treatment landscape, including the use of VEGF receptor inhibitors and some of the precision medicine treatments now identified for molecularly selected subsets of patients with differentiated thyroid cancer, such as BRAF, RET, and TRK inhibitors.

Two Fellows Use Online Resources to Boost Genetic Testing

April 16th 2022

Widespread germline testing in the United States could prevent cancer in hundreds of thousands of people. However, despite known benefits, uptake for genetic testing has been slow: only 1 in 5 individuals use recommended genetic services even when there is a significant family history of colorectal, breast, or ovarian cancer.